Safety Study of Nebulized Sodium Nitroprusside in Adult Acute Lung Injury
Status:
Unknown status
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
Acute lung injury (ALI) is caused by a wide variety of conditions, but always characterized
by hypoxia and non-cardiogenic pulmonary edema. Current treatment of ALI is supportive and
treatment of the underlying cause. New therapies to treat severe ALI have not been shown to
improve survival, and are limited by financial and logistical resources.
The investigators propose to investigate the role of inhaled sodium nitroprusside (iSNP) in
ALI. Sodium nitroprusside (SNP) is a vasodilator. When inhaled, SNP may travel to areas of
the lung participating in gas exchange, and cause the blood vessels surrounding these areas
to enlarge. This may result in an increase of blood vessels to these areas of the lung, and
improve oxygenation. Currently, iSNP has not been studied in the adult population. Therefore,
this study is intended to find the safety profile of varying doses of iSNP.